Based on the Takeda Pharmaceutical Co. Ltd. stock forecast from 0 analysts, the average analyst target price for Takeda Pharmaceutical Co. Ltd. is not available over the next 12 months. Takeda Pharmaceutical Co. Ltd.’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Takeda Pharmaceutical Co. Ltd. is Neutral, which is based on 7 positive signals and 7 negative signals. At the last closing, Takeda Pharmaceutical Co. Ltd.’s stock price was JPY 4,105.00. Takeda Pharmaceutical Co. Ltd.’s stock price has changed by -0.73% over the past week, -1.84% over the past month and +2.73% over the last year.
No recent analyst target price found for Takeda Pharmaceutical Co. Ltd.
No recent average analyst rating found for Takeda Pharmaceutical Co. Ltd.
Company Overview Takeda Pharmaceutical Co. Ltd.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan. Read Less
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapi...Read More
Frequently Asked Questions About Takeda Pharmaceutical Co. Ltd. (4502:TSE) Stock
Stock Target Advisor's fundamental analysis for Takeda Pharmaceutical Co. Ltd.'s stock is Neutral.
4502:TSE stock's dividend yield is 4.75%.
Our analysis grades 4502:TSE stock's dividend yield at A-. This means that 4502:TSE stock's dividend yield is above 91% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSE exchange.
Based on this 4502:TSE may be a good dividend stock for its sector.
Unfortunately we do not have enough data on 4502:TSE's stock to indicate what its average analyst target is.
4502:TSE stock's Price/Earning ratio is 22.68.
Our analysis grades 4502:TSE stock's Price / Earning ratio at F. This means that 4502:TSE stock's Price/Earning ratio is above 77% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSE exchange.
Based on this 4502:TSE may be a overvalued for its sector.
The last closing price of 4502:TSE's stock was JPY 4,105.00.
The most recent market capitalization for 4502:TSE is JPY 6,535.70B.
Unfortunately we do not have enough analyst data on 4502:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Takeda Pharmaceutical Co. Ltd.'s stock.
As per our most recent records Takeda Pharmaceutical Co. Ltd. has 49,281 Employees.
Takeda Pharmaceutical Co. Ltd.'s registered address is 1-1, Nihonbashi-Honcho 2-chome, Tokyo, Japan, 103-8668.
You can get more information about it from Takeda Pharmaceutical Co. Ltd.'s website at https://www.takeda.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Takeda Pharmaceutical Co. Ltd. (4502:TSE) Stock
Stock Target Advisor's fundamental analysis for Takeda Pharmaceutical Co. Ltd.'s stock is Neutral.
4502:TSE stock's dividend yield is 4.75%.
Our analysis grades 4502:TSE stock's dividend yield at A-. This means that 4502:TSE stock's dividend yield is above 91% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSE exchange.
Based on this 4502:TSE may be a good dividend stock for its sector.
Unfortunately we do not have enough data on 4502:TSE's stock to indicate what its average analyst target is.
4502:TSE stock's Price/Earning ratio is 22.68.
Our analysis grades 4502:TSE stock's Price / Earning ratio at F. This means that 4502:TSE stock's Price/Earning ratio is above 77% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the TSE exchange.
Based on this 4502:TSE may be a overvalued for its sector.
The last closing price of 4502:TSE's stock was JPY 4,105.00.
The most recent market capitalization for 4502:TSE is JPY 6,535.70B.
Unfortunately we do not have enough analyst data on 4502:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Takeda Pharmaceutical Co. Ltd.'s stock.
As per our most recent records Takeda Pharmaceutical Co. Ltd. has 49,281 Employees.
Takeda Pharmaceutical Co. Ltd.'s registered address is 1-1, Nihonbashi-Honcho 2-chome, Tokyo, Japan, 103-8668.
You can get more information about it from Takeda Pharmaceutical Co. Ltd.'s website at https://www.takeda.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4502:TSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
